Maintenance therapy in advanced non-small cell lung cancer: Evolution, tolerability and outcomes

Therapeutic Advances in Medical Oncology

Volumn 3, Issue 3, 2011, Pages 139-157

  Coate, Linda E ^a   Shepherd, Frances A ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

anti angiogenic; cetuximab; chemotherapy; erlotinib; gefitinib; maintenance; non small cell lung cancer; prolonged

Indexed keywords

ANTINEOPLASTIC AGENT; BELAGENPUMATUCE L; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; LBLP 25; LUCANIX; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM DERIVATIVE; STIMUVAX; SUNITINIB; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 79960262166     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834011399306     Document Type: Review

References (48)

1. Azzoli C.G. Baker S. Jr Temin S. Pao W. Aliff T. Brahmer J. et al (2009) American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27: 6251–6266.
2. Barata F.J. Parente B. Teixeira E.Ã.o. Nogueira F. Fernandes A. Cunha J.o. et al (2007) Optimal duration of chemotherapy in non-small-cell lung cancer: multicenter, randomized, prospective clinical trial comparing 4 vs 6 cycles of carboplatin and gemcitabine: P2-235. J Thoracic Oncol 2: S666–S666, DOI: 610.1097/1001.JTO.0000283943.0000270775.a0000283945.
3. Belani C.P. Barstis J. Perry M.C. La Rocca R.V. Nattam S.R. Rinaldi D. et al (2003) Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 21: 2933–2939.
4. Belani C.P. Waterhouse D.M. Ghazal H. Ramalingam S.S. Bordoni R. Greenberg R. et al (2010) Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 28(15 Suppl.): 7506–7507.
5. Blagden S.P. Charman S.C. Sharples L.D. Magee L.R. Gilligan D. (2003) Performance status score: do patients and their oncologists agree? Br J Cancer 89: 1022–1027.
6. Bradbury P.A. Shepherd F.A. (2008) Immunotherapy for lung cancer. J Thorac Oncol 3(6 Suppl. 2): S164–S170.
7. Bradbury P.A. Tu D. Seymour L. Ng R. Zhu L. Isogai P.K. et al (2008) Impact of clinical and molecular predictors of benefit from erlotinib in advanced non-small cell lung cancer on cost-effectiveness. J Clin Oncol (Meeting Abstracts) 26(15 Suppl.): 6531–6532.
8. Brodowicz T. Krzakowski M. Zwitter M. Tzekova V. Ramlau R. Ghilezan N. et al (2006) Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 52: 155–163.
9. Buccheri G.F. Ferrigno D. Curcio A. Vola F. Rosso A. (1989) Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study. Cancer 63: 428–432.
10. Butts C. Murray N. Maksymiuk A. Goss G. Marshall E. Soulieres D. et al (2005) Randomized phase IIB trial of BLP 25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 23: 6674–6681.
11. Cappuzzo F. Ciuleanu T. Stelmakh L. Cicenas S. Szczesna A. Juhasz E. et al (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11: 521–529.
12. Cappuzzo F. Ciuleanu T. Stelmakh L. Cicenas S. Szczesna A. Juhasz E. et al (2009) SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol (Meeting Abstracts) 27(15 Suppl.): 8001–8002.
13. Ciuleanu T. Brodowicz T. Zielinski C. Kim J.H. Krzakowski M. Laack E. et al (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374: 1432–1440.
14. D'Addario G. Fruh M. Reck M. Baumann P. Klepetko W. Felip E. (2010) Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl. 5): v116–v119.
15. Fidias P.M. Dakhil S.R. Lyss A.P. Loesch D.M. Waterhouse D.M. Bromund J.L. et al (2009) Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27: 591–598.
16. Fossella F.V. de Vore R. Kerr R.N. Crawford J. Natale R.R. Dunphy F. et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18: 2354–2362.
17. Goldie J.H. Coldman A.J. (1979) A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727–1733.
18. Hanna N. Shepherd F.A. Fossella F.V. Pereira J.R. de Marinis F. von Pawel J. et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (9): 1589–1597.
19. Kabbinavar F.F. Miller V.A. Johnson B.E. O'Connor P.G. Soh C. ATLAS Investigators (2010) Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 28(15 Suppl.): 7526–7527.
20. Kelly K. Chansky K. Gaspar L.E. Albain K.S. Jett J. Ung Y.C. et al (2008) Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26: 2450–2456.
21. Klein R. Wielage R. Muehlenbein C. Liepa A.M. Babineaux S. Lawson A. et al (2010) Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 5 (8): 1263–1272.
22. Liu G. Franssen E. Fitch M.I. Warner E. (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15: 110–115.
23. Miller V.A. O'Connor P. Soh C. Kabbinavar F. and for the ATLAS Investigators. (2009) A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 27(18 Suppl.): LBA8002–LBA8002.
24. NCCN (2010) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) v.2.2010.
25. Nemunaitis J. Dillman R.O. Schwarzenberger P.O. Senzer N. Cunningham C. Cutler J. et al (2006) Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 24: 4721–4730.
26. NICE (2010) www.nice.org.uk/guidance/TA181.
27. Park J.O. Kim S.W. Ahn J.S. Suh C. Lee J.S. Jang J.S. et al (2007) Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol 25: 5233–5239.
28. Perol M. Chouaid C. Milleron B.J. Gervais R. Barlesi F. Westeel V. et al (2010) Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol (Meeting Abstracts) 28(15 Suppl.): 7507–7508.
29. Pirker R. Pereira J.R. Szczesna A. von Pawel J. Krzakowski M. Ramlau R. et al (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373: 1525–1531.
30. Radzikowska E. Glaz P. Roszkowski K. (2002) Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol 13: 1087–1093.
31. Ramlau R. Gervais R. Krzakowski M. von Pawel J. Kaukel E. Abratt R.P. et al (2006) Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. J Clin Oncol 24: 2800–2807.
32. Reck M. von Pawel J. Zatloukal P. Ramlau R. Gorbounova V. Hirsh V. et al (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27: 1227–1234.
33. Rosell R. Robinet G. Szczesna A. Ramlau R. Constenla M. Mennecier B.C. et al (2008) Randomized phase II study of cetuximab plus cisplatin / vinorelbine compared with cisplatin / vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 19: 362–369.
34. Sandler A. Gray R. Perry M.C. Brahmer J. Schiller J.H. Dowlati A. et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542–2550.
35. Scagliotti G.V. Parikh P. von Pawel J. Biesma B. Vansteenkiste J. Manegold C. et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3543–3551.
36. Schiller J.H. Harrington D. Belani C.P. Langer C. Sandler A. Krook J. et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92–98.
37. Shepherd F.A. Dancey J. Ramlau R. Mattson K. Gralla R. O'Rourke M. et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095–2103.
38. Shepherd F.A. Rodrigues Pereira J. Ciuleanu T. Tan E.H. Hirsh V. Thongprasert S. et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123–132.
39. Smith I.E. O'Brien M.E. Talbot D.C. Nicolson M.C. Mansi J.L. Hickish T.F. et al (2001) Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 19: 1336–1343.
40. Socinski M.A. Schell M.J. Peterman A. Bakri K. Yates S. Gitten R. et al (2002) Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB / IV non-small-cell lung cancer. J Clin Oncol 20: 1335–1343.
41. Stinchcombe T. (2010) The role of maintenance therapy in advanced non-small cell lung cancer. ASCO Educational Book.
42. Takeda K. Hida T. Sato T. Ando M. Seto T. Satouchi M. et al (2010) Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol 28: 753–760.
43. Thatcher N. Chang A. Parikh P. Rodrigues Pereira J. Ciuleanu T. von Pawel J. et al (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527–1537.
44. Tourani J.M. Penaud D. Caubarrere I. Darse J. Balzon J.C. Boita F. et al (1990) Cisplatin and vindesine for disseminated non-small cell lung cancer. Results of a prospective trial with 81 patients. Bull Cancer 77: 1107–1113.
45. von Plessen C. Bergman B. Andresen O. Bremnes R.M. Sundstrom S. Gilleryd M. et al (2006) Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 95: 966–973.
46. Westeel V. Quoix E. Moro-Sibilot D. Mercier M. Breton J.L. Debieuvre D. et al (2005) Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst 97: 499–506.
47. Wheatley-Price P. Shepherd F.A. (2008 a) Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. Curr Opin Oncol 20: 162–175.
48. Wheatley-Price P. Shepherd F.A. (2008 b) Targeting angiogenesis in the treatment of lung cancer. J Thoracic Oncol 3: 1173–1184.